مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

164
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

94
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Omalizumab for treatment of chronic urticaria: A review of effective dose

Pages

  1-5

Abstract

 omalizumab (Xolair® ), a humanized anti-IgE monoclonal antibody, is effective and well-tolerated in patients with chronic spontaneous urticaria refractory to H1 antihistamines. The aim of this review was to present the effective dose of omalizumab for urticaria treatment in patients. Several databases, including PubMed, EMBASE, Scopus, Google, SID, Magiran, and Irandoc, were selected. The search process was performed using the keywords of Xolair, omalizumab, urticaria, Chronic urticaria, effect, and treatment. Sixty related articles were found. All studies have been conducted on people over 12 years of age with the exception of 2 articles investigating patients over 7 years old. Most studies have been performed on patients within the age range of 12-75 years and the maximum age of 81 years. omalizumab has been administered at different doses for patients with Chronic urticaria (75-600 mg). omalizumab has shown a treatment effect at all administered doses; however, it has the greatest effect when administered at the dose of 300 mg. The interval of subcutaneous injections was 2-6 weeks. In conclusion, the administration of omalizumab is effective at doses of 150 and 300 mg although the most effective dose is 300 mg.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    GHAFFARI, JAVAD, & GHAFFARI, NEGAR. (2019). Omalizumab for treatment of chronic urticaria: A review of effective dose. PHARMACEUTICAL AND BIOMEDICAL RESEARCH, 5(1), 1-5. SID. https://sid.ir/paper/763730/en

    Vancouver: Copy

    GHAFFARI JAVAD, GHAFFARI NEGAR. Omalizumab for treatment of chronic urticaria: A review of effective dose. PHARMACEUTICAL AND BIOMEDICAL RESEARCH[Internet]. 2019;5(1):1-5. Available from: https://sid.ir/paper/763730/en

    IEEE: Copy

    JAVAD GHAFFARI, and NEGAR GHAFFARI, “Omalizumab for treatment of chronic urticaria: A review of effective dose,” PHARMACEUTICAL AND BIOMEDICAL RESEARCH, vol. 5, no. 1, pp. 1–5, 2019, [Online]. Available: https://sid.ir/paper/763730/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button